Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.

Xuyang Song Robin Kate Kelley Anis A Khan Nathan Standifer Diansong Zhou KyoungSoo Lim Rajesh Krishna Lu Liu Kun Wang Patricia McCoon Alejandra Negro Philip He Megan Gibbs John F Kurland Ghassan K Abou-Alfa

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Our findings support novel insights into tremelimumab pharmacokinetics and exposure-response relationships in HCC and support the clinical utility of the STRIDE regimen in patients with uHCC.

Keyphrases

open label
clinical trial
radiation therapy
liver metastases
study protocol